123 related articles for article (PubMed ID: 34699460)
21. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
22. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis.
Volejnikova J; Mejstrikova E; Valova T; Reznickova L; Hodonska L; Mihal V; Sterba J; Jabali Y; Prochazkova D; Blazek B; Hak J; Cerna Z; Hrusak O; Stary J; Trka J; Fronkova E
Haematologica; 2011 Dec; 96(12):1815-21. PubMed ID: 21880630
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome.
Norén-Nyström U; Roos G; Bergh A; Botling J; Lönnerholm G; Porwit A; Heyman M; Forestier E
Leukemia; 2008 Mar; 22(3):504-10. PubMed ID: 18094715
[TBL] [Abstract][Full Text] [Related]
26. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
27. Influence of length of time to diagnosis and treatment on the survival of children with acute lymphoblastic leukemia: a population-based study.
Baker JM; To T; Beyene J; Zagorski B; Greenberg ML; Sung L
Leuk Res; 2014 Feb; 38(2):204-9. PubMed ID: 24333116
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of early response to treatment and its prognostic value in childhood acute lymphoblastic leukemia].
Cui L; Zhang RD; Gao C; Li WJ; Zhao XX; Zheng HY; Li ZG; Wu MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):298-303. PubMed ID: 24762995
[TBL] [Abstract][Full Text] [Related]
29. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M
JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872
[TBL] [Abstract][Full Text] [Related]
30. A 17-year experience with ALL-BFM protocol in acute lymphoblastic leukemia: prognostic predictors and interruptions during protocol.
Koka A; Saygin C; Uzunaslan D; Ozdemir N; Apak H; Celkan T
Leuk Res; 2014 Jun; 38(6):699-705. PubMed ID: 24720908
[TBL] [Abstract][Full Text] [Related]
31. Weekend delay in initiation of chemotherapy for acute lymphoblastic leukemia: does it matter?
Wahl SK; Gildengorin G; Feusner J
J Pediatr Hematol Oncol; 2012 Jan; 34(1):e8-e11. PubMed ID: 22146528
[TBL] [Abstract][Full Text] [Related]
32. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
33. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
34. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
35. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
36. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
37. BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia.
Avgeris M; Stamati L; Kontos CK; Piatopoulou D; Marmarinos A; Xagorari M; Baka M; Doganis D; Anastasiou T; Kosmidis H; Gourgiotis D; Scorilas A
Clin Chem Lab Med; 2018 Nov; 56(12):2104-2118. PubMed ID: 30016275
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia--a retrospective study by the Children's Cancer and Leukemia Study Group in Japan.
Okamoto T; Yokota S; Katano N; Seriu T; Nakao M; Taniwaki M; Watanabe A; Asami K; Kikuta A; Koizumi S; Kawakami T; Ohta S; Miyake M; Watanabe T; Iwai A; Kamitamari A; Ijichi O; Hyakuna N; Mimaya J; Fujimoto T; Tsurusawa M
Leuk Lymphoma; 2002 May; 43(5):1001-6. PubMed ID: 12148878
[TBL] [Abstract][Full Text] [Related]
39. Clinical Characteristics and Treatment Results of Childhood Acute Lymphoblastic Leukemia in North Macedonia.
Jovanovska A; Trakova-Antevska Z; Kocheva S; Stankovikj S; Panovska-Stavridis I; Dimovski A; Martinova K
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):37-47. PubMed ID: 33011702
[TBL] [Abstract][Full Text] [Related]
40. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
